#ViiVHealthcare's long-acting injectable #HIV treatment, #Cabenuva, has proved to be more effective than daily oral therapy for people in whom the virus is unsuppressed despite antiretroviral therapy (ART).
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social
@medicalprofref.bsky.socialIn adults and adolescents with unsuppressed HIV-1 on daily oral ART, switching to long-acting cabotegravir plus rilpivirine provided superior virologic suppression at 6 months. #HIV #Cabenuva https://www.empr.com/news/long-acting-cabenuva-superior-viral-suppression-unsuppressed-hiv/
@contagionlive.bsky.socialLong-acting cabotegravir plus rilpivirine (#Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6 months in treatment-experienced people with #HIV and detectable viremia in the phase 3b CROWN trial. #IDsky #Medsky
Learn more: www.contagionlive.com/view/long-ac...
